Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.
2.

Targeting the MET gene for the treatment of non-small-cell lung cancer.

Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.

Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Review.

PMID:
24355409
3.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Moldvay J, Peták I.

Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15. Hungarian.

4.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
5.
6.

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

Yamaoka T, Ohmori T.

Gan To Kagaku Ryoho. 2012 Jun;39(6):857-62. Review. Japanese.

PMID:
22705678
8.

Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.

Batus M, Fidler MJ, Bonomi PD.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1589-99. doi: 10.1586/era.10.104. Review.

PMID:
20942630
9.

Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.

Kani K, Sordella R, Mallick P.

Methods Mol Biol. 2012;795:233-53. doi: 10.1007/978-1-61779-337-0_16.

PMID:
21960227
10.

Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.

Heuckmann JM, Rauh D, Thomas RK.

J Clin Oncol. 2012 Sep 20;30(27):3417-20. doi: 10.1200/JCO.2012.43.1825. Epub 2012 Aug 20. No abstract available.

PMID:
22915655
11.

[Overcoming resistance to EGFR-TKI in lung cancer].

Takeda K.

Gan To Kagaku Ryoho. 2009 Apr;36(4):552-6. Japanese.

PMID:
19381026
12.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W.

Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Review.

13.

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.

Clark J, Cools J, Gilliland DG.

PLoS Med. 2005 Mar;2(3):e75. Epub 2005 Feb 22. No abstract available.

14.

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

Joshi VA, Kucherlapati R.

Pharmacogenomics. 2007 Sep;8(9):1211-20. Review.

PMID:
17924836
17.

Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer.

Settleman J, Kurie JM.

Cancer Cell. 2007 Jul;12(1):6-8. Review.

18.

Current management of advanced non-small cell lung cancer: targeted therapy.

Isobe T, Herbst RS, Onn A.

Semin Oncol. 2005 Jun;32(3):315-28. Review.

PMID:
15988686
19.
20.

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.

Barton S, Starling N, Swanton C.

Curr Cancer Drug Targets. 2010 Dec;10(8):799-812. Review.

PMID:
20718710

Supplemental Content

Support Center